Recombinant factor VIII may not abolish risk of new variant CJD from factor VIII

doi:10.1136/bmj.316.7141.1385

From trainee to consultant, BMJ Group offers doctors around the world tailored information, special events, learning resources and recruitment services at every step along their career path.

... by doctors, for doctors, for patients
We are open for entries!

Online learning

BMJ Learning

High-quality CME / CPD for doctors and other healthcare professionals. BMJ Learning features hundreds of accredited, peer-reviewed learning modules in text, video, and audio formats. Find out more

Courses and Qualifications

BMJ Masterclasses

BMJ Masterclasses, led by experts, help clinicians to use the latest evidence and recent guidelines in practice and meet their CPD/CME requirements. Find out more

Exam Preparation

The leading provider of online exam preparation, helping over 167,000 healthcare professionals to pass their exams. Find out more

onExamination

Search all BMJ comment articles:

From

Limit by

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

J P Betts, International technical affairs director

Grupo Grifols, Cambridge CB4 4GP

EDITOR—Barbara and Flanagan report the precautionary measures against new variant Creutzfeldt-Jakob disease that have been announced by the UK Department of Health.1 Unfortunately, the secretary of state announced the outcome of the NHS review of the provision of factor VIII for patients with haemophilia at the same time. The rationale for endorsing the use of recombinant factor VIII in children has thus become linked to concerns over new variant Creutzfeldt-Jakob.

Recombinant factor VIII is a biologically derived product produced by cell culture, not a synthetic product as stated in the announcement …